Clinical Trials Sponsored by AstraZeneca Turkey

Total 5368 results

AstraZeneca

Completed

Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer

Belgium, Canada, Austria, Australia
AstraZeneca

Completed

A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia (HoFH)

Malaysia, Canada, Taiwan, Belgium, Denmark, Israel
AstraZeneca

Completed

Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects

Kidney Failure, Chronic

United States
AstraZeneca

Completed

Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement (CLOUD)

COPD

Russian Federation
AstraZeneca

Completed

A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)

Hyperkalemia

Hong Kong
AstraZeneca

Completed

Proton Pump Inhibitor Empirical Treatment in Management of Outpatients With Gastroesophageal Reflux Disease.

Patients With Typical Symptoms of GERD (GERD Q >= 8)

China
AstraZeneca

Completed

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease (RISE)

COPD Patients

United States, Spain, Bulgaria, Mexico, Poland, South Africa, Germany, Argentina, Chile, Czechia, Puerto Rico
AstraZeneca

Completed

A Non-interventional Study to Investigate the Current Situation of Asthma-COPD Overlap Syndrome in Patients Over Age 40 With Persistent Airflow Limitation in China

Asthma-COPD Overlap Syndrome

China
AstraZeneca

Completed

Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

Type 2 Diabetes Mellitus

China
AstraZeneca

Completed

The Severity of Newly Diagnosed Asthma Patients and the Result of Initial 12 Weeks Treatment in China (INITIAL)

Asthma

China
AstraZeneca

Completed

Korean Post-marketing Surveillance for Onglyza®

Diabetes Mellitus, Type 2

Korea, Republic of
AstraZeneca

Completed

Post Marketing Surveillance of Roflumilast in Korea

Chronic Obstructive Pulmonary Disease

Korea, Republic of
AstraZeneca

Completed

Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes

Reflux Esophagitis

Japan
AstraZeneca

Completed

Non-inteRvEntional Study to Observe rAtionaLe to Select add-on TherapY for Type 2 Diabetes Inadequately Controlled With Metformin. (REALITY)

Type 2 Diabetes Mellitus

Bulgaria
AstraZeneca

Completed

An Observational Study of Respiratory Syncytial Virus (RSV) Hospitalizations in Preterm Infants (SENTINEL1)

Respiratory Syncytial Virus Hospitalizations

United States
AstraZeneca

Completed

Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

Type 2 Diabetes

Korea, Republic of, Mexico, South Africa, United States, Canada, Puerto Rico, Poland, Romania
AstraZeneca

Terminated

Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
AstraZeneca

Completed

Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions

Pharmacokinetics | Relative Bioavailability | AUC | Cmax

United States
AstraZeneca

Completed

Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010/CA-101) (POPCICLE)

Asthma

Canada, Hungary, South Africa
AstraZeneca

Completed

Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD (OPTIMIZE)

Chronic Obstructive Pulmonary Disease (COPD)

Slovakia
AstraZeneca

Completed

AZD8108 SAD/MAD in Healthy Volunteers (AZD8108)

Healthy Volunteers

United States
AstraZeneca

Completed

A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years

Healthy Japanese Children Age 7 Years Through 18 Years

Japan
AstraZeneca

Completed

To Determine the Relative Bioavailability of Different Formulations of AZD9291 and the Effect of Food.

Healthy Volunteers

United States
AstraZeneca

Completed

Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins

Type 2 Diabetes

United States
AstraZeneca

Completed

Clinical Outcomes of Exenatide Versus Basal Insulin

Type 2 Diabetes

United Kingdom
AstraZeneca

Completed

Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)

Carcinoma, Non-Small-Cell Lung

Japan
AstraZeneca

Completed

Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Australia, Canada, New Zealand
AstraZeneca

Completed

A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Opioid-Induced Constipation (OIC)

United States, Germany, Australia, Slovakia
AstraZeneca

Completed

Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination

Chronic Obstructive Pulmonary Disease (COPD)

Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Romania, Russian Federation, Slovakia, South Africa, Spain, Sweden, Ukraine, United Kingdom
AstraZeneca

Terminated

Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease (TREAT)

Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation

United Kingdom
AstraZeneca

Completed

Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States
AstraZeneca

Completed

Effect of High Dose Ciclesonide on Asthma Control (CONTRAST)

Bronchial Asthma

Germany, Israel, Brazil, Russian Federation, Argentina
AstraZeneca

Completed

Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia

Seasonal Allergic Rhinitis

Russian Federation
AstraZeneca

Completed

Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.

Asthma

Russian Federation, Hungary, South Africa, Mexico, United States, Poland
AstraZeneca

Completed

Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)

Asthma

Canada
AstraZeneca

Completed

Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.

Type 2 Diabetes

United States
AstraZeneca

Completed

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)

Chronic Obstructive Pulmonary Disease (COPD)

France, Germany, United Kingdom, United States, Australia, Austria, Brazil, Hungary, New Zealand, Romania, Russian Federation
AstraZeneca

Completed

Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours

Solid Tumours

Netherlands, Belgium
AstraZeneca

Completed

Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3

Asthma

Sweden, Netherlands, Canada
AstraZeneca

Completed

Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Japanese Subjects

Pharmacokinetics | Bioequivalence | Healthy Japanese Subjects

United Kingdom
AstraZeneca

Completed

A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Canada
AstraZeneca

Completed

Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)

Chronic Obstructive Pulmonary Disease

United States, Canada
AstraZeneca

Completed

Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Argentina, Australia, Canada, Mexico, New Zealand, South Africa
AstraZeneca

Completed

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC (IFUM)

Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Bulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
AstraZeneca

Completed

Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (REGAL)

Recurrent Glioblastoma

United States, Australia, France, United Kingdom, Germany, Netherlands, Canada, Austria, Belgium, Czech Republic
AstraZeneca

Completed

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS) (REACT)

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Austria, Belgium, Germany, Greece, Russian Federation, Australia, Brazil, Canada, Denmark, France, Hungary, Israel, Italy, Netherlands, Poland, Slovakia, South Africa, Spain, Turkey, United Kingdom
AstraZeneca

Completed

Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 y) (BY9010/M1-206)

Asthma

South Africa, Germany, Brazil, Hungary, Poland, Portugal
AstraZeneca

Completed

Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)

Allergic Rhinitis | Perennial Allergic Rhinitis | Hay Fever

United States
AstraZeneca

Completed

Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128) (HELIOS)

Chronic Obstructive Pulmonary Disease

France, Germany, Italy, Spain, United Kingdom, Austria, Hungary
AstraZeneca

Completed

Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101)

Asthma

Argentina

3

Subscribe